The research focused on four flavonoids, a family of polyphenolic compounds abundant in fruits, vegetables, and herbs: quercetin, kaempferol, luteolin, and apigenin. These molecules are structurally close relatives, differing only in the arrangement of hydroxyl groups on their carbon skeleton, yet the study found that they behave in strikingly different ways inside the body. Rather than acting as interchangeable antioxidants, each compound appeared to specialize in a different stage of the gut-brain cascade, a finding with real implications for how functional foods and supplements might be designed in the future.

To test the compounds, the researchers induced colitis in mice, creating an animal model that mirrors the intestinal inflammation and barrier disruption seen in human inflammatory bowel disease. The animals then received one of the four flavonoids, and the team measured everything from stool consistency and colon inflammation to the composition of the gut microbiome, the integrity of the intestinal wall, and the behavior of the mice in standardized memory tests. All four flavonoids eased the severity of colitis, but the picture became far more interesting when the investigators looked at the brain.

In tests of recognition memory and spatial working memory, specifically the novel object recognition test and the Y-maze, kaempferol and quercetin stood out as the most effective at rescuing cognitive performance. Mice treated with these two compounds explored novel objects and navigated the maze in ways that indicated their memory had substantially recovered, while untreated colitic mice showed the expected deficits. This separation between compounds that calm the gut and compounds that also rescue the brain suggests that suppressing intestinal inflammation alone is not sufficient to protect cognition.

Inside the brain, the team examined the cellular drivers of neuroinflammation. Microglia, the resident immune cells of the central nervous system, become overactivated during systemic inflammation and release signaling molecules that can damage synapses and impair learning. The flavonoid treatments suppressed this microglial activation, but apigenin showed a unique additional property: it was the only compound that reversed the overactivation of astrocytes, the star-shaped glial cells that support neurons but can become reactive and harmful during chronic inflammation. Meanwhile, quercetin and apigenin elevated levels of hippocampal synaptic proteins, molecular markers suggesting that the physical connections underlying memory were being preserved or rebuilt.

The mechanistic story continued in the gut itself. Apigenin and luteolin upregulated tight junction proteins, the molecular staples that seal the gaps between intestinal epithelial cells and prevent bacteria and their toxins from crossing into the bloodstream. Quercetin, for its part, produced a measurable drop in intestinal permeability, confirmed by a significant decrease in FITC-dextran flux, a standard laboratory technique in which a fluorescent sugar is fed to an animal and its appearance in the blood reveals how much leaked through the gut wall. A statistically significant reduction in this flux means the intestinal barrier was physically tighter in quercetin-treated animals.

Equally important were the changes in the gut microbiome. The four flavonoids reshaped the composition of gut bacteria in different ways, and here kaempferol emerged as the champion of microbial diversity, restoring the Shannon index, a standard measure of both species richness and evenness, to near-healthy levels with high statistical confidence. Quercetin and kaempferol both enriched beneficial genera, including Bifidobacterium and Lactobacillus, organisms long associated with anti-inflammatory effects and the production of short-chain fatty acids that nourish both the colon and, via the vagus nerve and the bloodstream, the brain.

To tie these threads together, the researchers used redundancy analysis, a statistical method that relates multiple environmental variables to community composition, and confirmed significant correlations between intestinal barrier integrity, microbiota structure, and cognitive scores. In other words, the mice with the tightest gut walls and the healthiest microbial communities were also the mice that performed best on memory tasks. This triangulated evidence supports the gut-brain axis model in which a compromised intestinal barrier permits inflammatory signals and microbial products to travel systemically, ignite neuroinflammation in the hippocampus, and erode cognitive function.

What makes the study conceptually significant is the demonstration that structurally similar molecules are not functionally interchangeable. Kaempferol excelled at rebuilding microbial diversity, quercetin at tightening the barrier and enriching probiotic bacteria, apigenin at calming astrocytes and boosting synaptic proteins, and luteolin at reinforcing tight junctions. The authors argue that these distinct yet complementary roles point toward a multi-targeted dietary strategy, in which combinations of flavonoids could simultaneously protect the microbiome, the intestinal wall, and the brain, rather than relying on any single compound to do everything.

The findings are, for now, confined to a mouse model, and the doses, timing, and long-term safety in humans remain open questions that will require clinical trials. Flavonoid bioavailability also varies widely depending on food matrix and gut metabolism, so translating these results into dietary recommendations will demand careful work. Still, the study adds to a rapidly growing body of evidence that what happens in the gut does not stay in the gut, and that everyday plant compounds found in onions, kale, celery, parsley, and citrus may hold precise, mechanistically distinct tools for protecting the brain from the downstream consequences of intestinal disease.

Subject of Research: Effects of dietary flavonoids on the gut microbiota, intestinal barrier, and colitis-driven cognitive impairment via the gut-brain axis

Article Title: Four dietary flavonoids differentially modulate the gut microbiota–barrier interaction against colitis-driven cognitive deficits

Article References: Li, Q., Qiao, S., Nie, X., Li, Y., Zhang, W., Chen, X., Xie, J., & Nie, S. (2026). Four dietary flavonoids differentially modulate the gut microbiota–barrier interaction against colitis-driven cognitive deficits. npj Science of Food. https://doi.org/10.1038/s41538-026-01191-x

Image Credits: AI Generated

DOI: 10.1038/s41538-026-01191-x

Keywords: flavonoids, quercetin, kaempferol, luteolin, apigenin, gut-brain axis, colitis, inflammatory bowel disease, gut microbiota, intestinal barrier, neuroinflammation, cognitive impairment

The team, led by Yimei Zheng, Boyu Chen and colleagues at Guangdong Ocean University, built a self-microemulsifying drug delivery system, or SME, around luteolin. These systems are concentrated mixtures of oil, surfactant and co-surfactant that remain as clear liquids in a capsule but spontaneously bloom into nanoscale droplets, typically 20 to 100 nanometers across, the moment they meet gastrointestinal fluid. The sudden explosion of surface area dissolves lipophilic molecules that would otherwise sit undissolved in the gut lumen, protects them from oxidation and pH swings, and presents them to the intestinal epithelium in a form cells readily accept. What distinguishes this formulation from most previous nanocarriers is the deliberate choice of emulsifier: D-α-tocopheryl polyethylene glycol 1000 succinate, better known as TPGS, a Food and Drug Administration-approved amphiphilic polymer that happens to be a potent inhibitor of P-glycoprotein itself.

Formulation development began with pseudo-ternary phase diagrams, a classical pharmaceutical tool for mapping where oil, surfactant and water coexist as a stable microemulsion. The researchers combined TPGS as surfactant, polyethylene glycol 400 as co-surfactant and isopropyl myristate as the oil phase, titrating water into 25 different compositions and watching for turbidity and phase separation. The sweet spot emerged at a TPGS-to-PEG 400 mass ratio of 2:1, which produced the largest microemulsion region. Below that ratio, insufficient TPGS left interfacial tension too high; above it, the relative shortage of PEG 400 compromised co-solubilization. Oil content mattered just as much: higher proportions of isopropyl myristate destabilized the system by diluting the emulsifiers, echoing earlier reports that oil fractions above roughly 40 percent tend to yield unstable emulsions.

Three candidate formulations, designated TP12-I2, TP11-I2 and TP21-I3, were loaded with luteolin at 50 milligrams per gram of carrier and put through a demanding characterization gauntlet. Dynamic light scattering showed narrow, monomodal size distributions with mean droplet diameters below 50 nanometers. The formulations survived alternating 4 and 45 degree Celsius cycles, freeze-thaw swings between minus 20 and 25 degrees, and centrifugal stress in a LUMiSizer analyzer without significant changes in droplet size or visible phase separation. Transmission electron microscopy confirmed uniform, spherical particles with no aggregation. Fourier-transform infrared spectroscopy revealed subtle shifts in luteolin’s phenolic C–O stretch at 1265 wavenumbers and its carbonyl band moving from 1656 to 1653 wavenumbers, fingerprints of hydrogen bonding between the drug and its carrier, while ultraviolet-visible spectra retained luteolin’s characteristic 255 and 350 nanometer peaks, proving the molecule emerged chemically intact.

Release and antioxidant performance both improved markedly. In dialysis experiments, free luteolin plateaued after about 12 hours with only 9.23 percent cumulative release, whereas the encapsulated drug kept diffusing past the 24-hour mark, reaching 39.43 percent, a 4.3-fold enhancement driven by the enormous oil-water interfacial area of the nanodroplets. In DPPH and ABTS radical-scavenging assays, the SME formulations outperformed free luteolin at equivalent concentrations, an effect the authors attribute partly to improved solubility and partly to TPGS itself, which contributed measurable radical-scavenging activity of its own. Dye dispersion and conductivity experiments traced how the formulation behaves in the gut: below 40 percent water it forms water-in-oil structures, transitions through a bicontinuous phase between 40 and 70 percent, and completes inversion to a gut-friendly oil-in-water microemulsion above 70 percent hydration.

The cellular story is where the design philosophy pays off. Using Caco-2 monolayers, the gold-standard model of the intestinal barrier, the team showed that luteolin-SME accumulated inside cells at significantly higher levels than free luteolin within 15 minutes, with uptake rising linearly for an hour before slowing. Cooling cells to 4 degrees Celsius slashed uptake, proving the process is energy-dependent, and a panel of endocytosis inhibitors pinpointed the routes: chlorpromazine and nystatin, which block clathrin-mediated and caveolae-mediated pathways respectively, both suppressed uptake, while amiloride, a macropinocytosis blocker, had no significant effect. The nanodroplets, in short, enter intestinal cells through the same receptor-driven machinery cells use to internalize nutrients.

The P-glycoprotein evidence is the study’s most layered contribution. Verapamil and cyclosporine A, two canonical efflux inhibitors, each boosted luteolin uptake, confirming the flavonoid is a genuine P-gp substrate. TPGS alone also increased intracellular luteolin, and a rhodamine 123 assay showed that luteolin-SME reduced P-gp efflux activity in a concentration-dependent manner. Western blotting then revealed something subtler: the formulation downregulated total P-gp protein expression, with the effect scaling with TPGS content, suggesting both immediate functional blockade and a longer-term suppression of the pump itself. Molecular docking simulations tied the mechanism together at the atomic level, showing TPGS and luteolin bind the same substrate pocket of P-gp with binding energies of minus 8.0 and minus 7.2 kilocalories per mole, both hydrogen-bonding to the GLN-191 and THR-195 residues. TPGS, in other words, acts as a competitive antagonist that physically occupies the pump’s recognition site.

Permeability and pharmacokinetics translated the cellular mechanisms into whole-body numbers. Across validated Caco-2 monolayers with transepithelial electrical resistance near 900 ohms per square centimeter, the apparent permeability coefficients of the SME formulations ran 2.8 to 3.5 times higher than free luteolin, aided by a transient, fully reversible 25 to 35 percent loosening of tight junctions that recovered within 24 hours. In mice given 200 milligrams per kilogram orally, the area under the plasma concentration-time curve soared from 8.628 to 247.729 milligrams per liter times hours, a 29-fold increase, while peak plasma concentration jumped 16-fold from 1.705 to 27.546 milligrams per liter. Mean residence time lengthened from 3.889 to 6.57 hours, the half-life extended, and clearance dropped dramatically. Fluorescent biodistribution imaging with the dye DiR showed the formulation lingering in the intestine at 10 hours, long after the free-probe signal had vanished, and concentrating more strongly in liver and kidney.

Therapeutically, the payoff appeared in inflammation models. In lipopolysaccharide-stimulated RAW264.7 macrophages, luteolin-SME cut nitric oxide, TNF-α and IL-6 by roughly 77, 49 and 48 percent relative to the inflamed group, restored catalase and superoxide dismutase activities, suppressed the lipid peroxidation marker MDA, and reduced reactive oxygen species far more effectively than free luteolin, while nudging macrophage morphology from a pro-inflammatory M1 state toward an anti-inflammatory M2-like phenotype and protecting mitochondrial membrane potential. In an LPS-induced sepsis model in mice, the formulation lowered serum TNF-α, IL-6 and IL-1β by about 37, 26 and 39 percent, reduced the liver enzymes ALT and AST by roughly 65 and 64 percent, and preserved near-normal hepatic architecture under the microscope. Biosafety testing showed no cytotoxicity across intestinal, liver and macrophage cell lines and hemolysis rates below 5 percent. The authors present the platform as a general solution for poorly soluble, efflux-limited natural products, a class that includes many of the flavonoids now being studied for chronic inflammatory disease, and the 29-fold bioavailability leap suggests the strategy deserves close attention from anyone trying to turn promising plant chemistry into medicine that actually reaches the bloodstream.

Subject of Research: A TPGS-functionalized self-microemulsifying drug delivery system that enhances the oral bioavailability and anti-inflammatory efficacy of the flavonoid luteolin by inhibiting P-glycoprotein efflux.

Article Title: Boosting luteolin bioavailability via P-glycoprotein efflux inhibition: a self-microemulsifying drug delivery systems

Article References: Zheng, Y., Chen, B., Huang, X., Ai, C., Teng, H., & Chen, L. (2026). Boosting luteolin bioavailability via P-glycoprotein efflux inhibition: a self-microemulsifying drug delivery systems. Journal of Advanced Research, 88, 1095-1117. https://doi.org/10.1016/j.jare.2026.01.030

Image Credits: AI Generated

DOI: 10.1016/j.jare.2026.01.030

Keywords: luteolin, self-microemulsifying drug delivery system, TPGS, P-glycoprotein, oral bioavailability, flavonoids, Caco-2 cells, pharmacokinetics, anti-inflammatory, antioxidant, nanocarriers, sepsis

The clinical backdrop is sobering. Ulcerative colitis, a chronic inflammatory disease of the colon, now affects an estimated five million people worldwide, with incidence climbing steadily and peaking in two age bands, between 15 and 30 and again between 50 and 70 years. Its most feared complication is colitis-associated colorectal cancer, a malignancy that emerges through a cascade of chronic inflammation, persistent oxidative stress, immune dysregulation, and cumulative DNA damage in the intestinal epithelium. Colorectal cancer overall is already the third most diagnosed cancer and the second leading cause of cancer death globally, and projections suggest deaths from colon and rectal cancers will rise by roughly 60 and 71.5 percent respectively by 2035. Conventional treatments, from mesalazine and corticosteroids to biologics such as infliximab, help many patients but carry toxicity, drug resistance, and high costs, fueling the search for safer adjunctive agents.

That is where the honeysuckle flower enters. The review catalogs its principal bioactive constituents across five chemical families: volatile oils such as linalool, geraniol, and eugenol; flavonoids including luteolin, quercetin, kaempferol, and apigenin; phenolic acids dominated by chlorogenic acid; triterpenoid saponins such as loniceroside A and B; and high-molecular-weight polysaccharides built from glucose, galactose, and mannose. Chlorogenic acid, an ester of caffeic and quinic acid produced via the shikimate pathway, is the most abundant and is the compound the Chinese Pharmacopeia uses as a quality benchmark, mandating at least 1.5 percent on a dry-weight basis along with a total phenolic acid content of 3.8 percent. Structural features matter: the phenolic hydroxyl groups donate hydrogen atoms to neutralize free radicals, while carboxyl groups participate in acid–base interactions with target proteins, underpinning the molecule’s antioxidant and anti-inflammatory versatility.

The mechanistic core of the review concerns how these compounds tame ulcerative colitis. Despite their chemical diversity, the constituents converge on remarkably similar pathways. Geraniol, administered orally in mouse models, reduced the pro-inflammatory cytokines TNF-α, IL-1β, and IL-6 by modulating nuclear factor kappa B, or NF-κB, a master transcription factor that switches on broad programs of inflammation-related genes. Luteolin suppressed the inhibitor of κB kinase α/β, blocking NF-κB signaling and preventing macrophage activation and chemotactic migration, while simultaneously raising levels of the anti-inflammatory cytokine IL-10 and restoring the colonic barrier damaged by dextran sulfate sodium, a standard chemical inducer of experimental colitis. Chlorogenic acid, meanwhile, dampens both the NF-κB and MAPK cascades, including the ERK, p38, and JNK branches, reducing inflammatory mediators, oxidative stress, and apoptosis in injured mucosa.

Oxidative stress and barrier integrity form a second line of defense. In colitic mice, luteolin and chlorogenic acid both increased the activities of the antioxidant enzymes superoxide dismutase and glutathione peroxidase while lowering malondialdehyde, a marker of lipid peroxidation, helping epithelial cells withstand reactive oxygen species. Quercetin improved tight junction integrity in an aryl hydrocarbon receptor–dependent manner, and kaempferol raised expression of the junctional proteins zonula occludens-1, occludin, and claudin-1, physically sealing the gaps through which bacteria and endotoxins translocate into the gut wall. On the immune side, luteolin shifted macrophages from a pro-inflammatory M1 phenotype toward the reparative M2 state through an AMPK–PPARγ pathway, quercetin inhibited the cGAS–STING pathway in intestinal macrophages, and chlorogenic acid restored the Th1/Th2 lymphocyte balance while making dendritic cells more tolerogenic.

Perhaps the most striking findings involve the gut microbiota. The volatile oils disrupt the membranes of pathogens such as Escherichia coli and Salmonella, while luteolin enriched beneficial commensals including Roseburia and butyrate-producing bacteria, whose short-chain fatty acid outputs nourish the colonic epithelium and dampen inflammation. Chlorogenic acid boosted Bifidobacterium, Lactobacillus, and Akkermansia while suppressing harmful species, and honeysuckle polysaccharides acted as prebiotics at doses of 150 milligrams per kilogram in mice, promoting probiotic growth, stimulating secretory IgA secretion, and upregulating tight junction proteins. The review frames this as a feedback loop: a healthier microbial community produces more anti-inflammatory metabolites, which in turn reinforce the mucosal barrier and push the disease toward remission.

Against colorectal cancer itself, the constituents act on several fronts. Chlorogenic acid downregulated the anti-apoptotic protein Bcl-2, activated caspase-3 and caspase-9, elevated p53 and p21, and induced G1-phase cell cycle arrest in HT-29 colon cancer spheroids at high concentrations. Kaempferol triggered apoptosis in HT-29 cells through both mitochondrial and death receptor pathways, promoting cytochrome C release and PARP cleavage, and in a lung metastasis model it curbed migration by downregulating a circular RNA that activates the JMJD2C/β-catenin pathway. Luteolin reduced Cyclin D1 and CDK4 to slow proliferation and suppressed the matrix metalloproteinases MMP-2 and MMP-9, enzymes that degrade the extracellular matrix and enable invasion, while upregulating E-cadherin to counter epithelial–mesenchymal transition. Quercetin and apigenin induced G2/M and G0/G1 arrest respectively and modulated the PI3K/Akt, Wnt/β-catenin, and JAK/STAT pathways that drive tumor progression.

Even the tumor microenvironment may be within reach. Honeysuckle extracts and a constituent microRNA called miRNA2911 suppressed murine colorectal tumor growth by downregulating TGF-β1 and enhancing T cell infiltration into tumors, hinting at an immunomodulatory mechanism. A phenolic acid derivative, caffeic acid phenethyl ester, inhibited NLRP3 inflammasome activation and protected mice from chemically induced colitis-associated cancer. The review also notes that shifting tumor cell metabolism away from excessive glycolysis toward oxidative phosphorylation can reduce lactate, ease the acidic tumor milieu, and improve infiltration of CD8-positive and CD4-positive T cells, a metabolic angle that polyphenol-rich plants may exploit.

The authors are candid about the caveats. Most evidence comes from cell cultures and animal models using doses far above what dietary consumption delivers, such as 2000 micromolar chlorogenic acid in vitro, so bioavailability, pharmacokinetics, and physiologically relevant exposures remain uncertain. Chemical composition varies with geography, harvest season, and processing, complicating standardization, and no large-scale clinical trials have yet established dosing guidelines for ulcerative colitis or colorectal cancer. Still, the translational pathway is taking shape: microencapsulation, nanoemulsions, and liposomal delivery could protect the heat- and light-sensitive compounds and improve intestinal absorption, while coformulation with probiotics may amplify microbiota-mediated benefits. Already consumed daily as honeysuckle tea across East Asia, the flower may be less a folk curiosity than a functional food ingredient in waiting, one whose centuries of empirical use are finally being translated into molecular language.

Subject of Research: Bioactive constituents of Lonicerae Japonicae Flos and their modulation of gut health, ulcerative colitis, and colorectal cancer

Article Title: Lonicerae Japonicae Flos as a Dietary Natural Product: Bioactive Constituents, Gut Health Modulation, and Therapeutic Potential in Ulcerative Colitis and Colorectal Cancer

Article References: Huang, X., Zhang, L., Shi, Z., Zhu, N., Liu, Y., & Zhou, Y. (2026). Lonicerae Japonicae Flos as a Dietary Natural Product: Bioactive Constituents, Gut Health Modulation, and Therapeutic Potential in Ulcerative Colitis and Colorectal Cancer. Food Science & Nutrition, 14(9), Article e72366. https://doi.org/10.1002/fsn3.72366

Image Credits: AI Generated

DOI: 10.1002/fsn3.72366

Keywords: honeysuckle, Lonicerae Japonicae Flos, ulcerative colitis, colorectal cancer, chlorogenic acid, luteolin, gut microbiota, NF-κB, flavonoids, traditional Chinese medicine, functional foods, intestinal barrier